Jolyon Martin
Co-Founder and Head of Business Development, PetMedix
Jolyon is one of the founders of, and now head of business development for, PetMedix Ltd, a Cambridge, UK based biotechnology company. PetMedix is developing therapeutic antibodies for dogs and cats using a platform developed during Jolyon’s PhD in the laboratory of Prof Allan Bradley, co-founder and CSO of PetMedix.
Moving from the lab into a commercial role at PetMedix, Jolyon led the work to secure the company’s partnership deals with Boehringer Ingelheim and Zoetis. He has also been deeply involved in raising the $50M PetMedix has secured to date, as well as IP, Licensing, Comms, and Marketing projects across the company. Beyond his commercial roles, Jolyon is also the chair of PetMedix’s Green Group, which seeks to reduce or mitigate the environmental impact of the company.
As the inventor on the patents covering PetMedix’s platform and author of the thesis that describes it, he is uniquely positioned to apply his technical knowledge of the science underpinning the company to its commercial advantage. In 2021 Jolyon was named on the Forbes 30 Under 30 Europe List of top entrepreneurs in the Science and Healthcare category.
